Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Completed · Not applicable · Has a placebo group

Conditions studied: Cognitive Aging

In brief

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

Key facts

Study ID

NCT00935493

Run by

Yale University

People needed

154

Starts

2009-06-01

Expected to finish

2012-08-01

Last updated by the study team

2014-08-13

Who can join

Age: 75 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects enrolled will be nondemented, male and female individuals who meet the following inclusion criteria:
• 75 years of age or older
• Fluent in English
• Stable medical condition for at least 4 weeks prior to Screening visit
• Stable dose of non-excluded medications for at least 4 weeks prior to Screening visit

You may not qualify if…

• Dementia
• Mild Cognitive Impairment (Amnestic MCI)
• Clinically significant neurologic disease
• Clinically significant or unstable medical conditions that would interfere with participation in the trial
• Known hypersensitivity to guanfacine
• History of alcohol or substance abuse or dependence within the past 5 years
• Active major psychiatric disorders, including major depression
• History of mental retardation
• Significant abnormalities on clinical laboratories, ECG, or physical examination
• Impairment of visual or auditory acuity sufficient to interfere with completion of study procedures
• Education level < 6 years

Where it is running

• Alzheimer's Disease Research Unit, Yale University School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.